BioSpace News Archive

STEMCELL Technologies is pleased to announce the acquisition of Propagenix Inc.

ONWARD Medical N.V. announces that the Company will participate in the Degroof Petercam Healthcare Conference this month.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,500 shares of its common stock to nine newly-hired employees, with a grant date of January 18, 2024.

Aadi Bioscience, Inc. announced poster presentations at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.41 per share.

Kyverna Therapeutics, Inc. today announced it received fast track designation by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of multiple sclerosis (MS).

Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization.

Zealand Pharma A/S today announces the receipt on 18 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from J O Hambro Capital Management.

Tampa General Hospital announced that the TGH Cancer Institute recently completed Florida’s first successful infusion of Hemgenix, a gene therapy option for patients with severe hemophilia B — a rare bleeding disorder characterized by failure of the blood to clot properly.